Skip to main content

Table 1 Overall CML Patient Characteristics (n = 87 patients)

From: Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study

Characteristic # of Patients (%)
Age in years (n = 86)  
   <60 79 (91.9%)
   >/=60 7 (8.1%)
Gender (n = 87)  
   Male 44 (50.6%)
   Female 43 (49.4%)
Ethnicity (n = 87)  
   Hispanic 53 (60.9%)
   Non-Hispanic 34 (39.1%)
White 4 (4.6%)
African American 10 (11.5%)
Asian 20 (23.0%)
Imatinib Treatment (n = 64)  
   Yes 40 (62.5%)
   No 24 (37.5%)
Hemoglobin (g/dL) (n = 83)  
   <12 57 (68.7%)
   >/=12 26 (31.3%)
WBC count (× 109/L) (n = 85)  
   <50 22 (25.9%)
   >/=50 63 (74.1%)
Platelets (× 109/L) (n = 82)  
   <450 50 (61.0%)
   >/=450 32 (39.0%)
CML Phase (n = 74)  
   Chronic 68 (91.9%)
   Accelerated 4 (5.4%)
   Blastic 2 (2.7%)
Hasford Score (n = 64)  
   </=780 low-risk 35 (54.7%)
   >780 and </=1480 intermediate 21 (32.8%)
   >1480 high-risk 8 (12.5%)
Sokal Score (n = 65)  
   <0.8 good prognosis 25 (38.5%)
   0.8–1.2 moderate prognosis 24 (36.9%)
   >1.2 poor prognosis 16 (24.6%)
CHR at 3 months, all treatments (n = 47)  
   Yes 28 (59.6%)
   No 19 (40.4%)
CHR at 3 months, imatinib only (n = 36)  
   Yes 27 (75%)
   No 9 (25%)
  1. Demographic and clinical features of CML patients presenting initially at LAC+USC Medical Center are presented.